JUSH · Jushi Holdings Inc.
Market Cap
$109.43M
Shares
199.70M
Volume · Oct 21
159.93K
Avg daily vol (3M)
179.73K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.55
Open$0.46
Day$0.46–0.57
52W close$0.35–0.84
Avg vol 30d203K
Short int742K · 0.4% float · 1.3d
Short vol4%
Last earningsOct 28, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 28, 2026
Scheduled
· in 1 wks
filed Jul 28, 2026
call held Jul 28, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$271.75M
Trailing 12 months
Net income (TTM)
−$66.42M
Trailing 12 months
Revenue growth YoY
+9.6%
Year over year
Operating margin
2.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
6.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$196.67M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.5%
Year over year · more shares
Price change (1Y)
-19.5%
Trailing year
Short interest
0.4%
Latest settlement · 1.3 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 28, 2026
Q2 FY26
TL;DR. Jushi reported Q2 revenue up 9.6% YoY to $71.3M with record wholesale revenue of $9.4M (+68%) and record Virginia retail revenue, while federal rescheduling eliminated Section 280E yielding a $6.4M discrete tax benefit; however, adjusted EBITDA margin compressed to 18.7% from 21.1% (which included $4M of non-recurring ERTC income) and the company posted a $7.3M net loss with $219.8M of gross debt outstanding.
Bullish
- + Q2 revenue grew 9.6% YoY to $71.3M with wholesale up 68% to a record $9.4M and record Virginia retail revenue
- + Federal rescheduling eliminated Section 280E for qualifying medical cannabis, producing a $6.4M discrete tax benefit in Q2 and potential further ~$9M H2 reduction
- + Virginia adult-use legislation enacted with sales commencing July 1, 2027, unlocking a $2-3B illicit/unregulated market opportunity
- + Operating cash flow improved to $9.4M in H1 2026 from $5.6M in H1 2025
Bearish
- − Adjusted EBITDA margin compressed to 18.7% from 21.1% on retail pricing pressure and promotional activity
- − Net loss of $7.3M for the quarter with $9.9M of interest expense and $219.8M of gross debt outstanding
- − Prior-year quarter included $4M non-recurring ERTC income that did not recur, and a $1.5M impairment charge was recognized for dispensaries pending relocation
- − Q2 SG&A rose to $29.3M from $28.7M on higher employee costs from expanded operations
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
0%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
40%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
+5%
trailing
YTD return
−13%
this year
Relative strength
−2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Flat
0% holders QoQ
Insider flow
Accumulating
Net +$1.0M over 90 days · 0% sells
Short interest
Rising
0.37% of float · ▲ +299.5% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
2 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+2%
Y/Y
Gross margin
43%
contracting
EPS growth
−40%
Y/Y
Free cash flow
$1.6M
Balance sheet
$181.8M
net debt
Quant / Vol
risk profile
Volatility
129%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
11.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jul 28, 2026
during the second half of the year
Reduction in additional income tax expense and related uncertain
$9M
full-year
Full-year maintenance and gross capital expenditures
$10M – $13M
Guided vs delivered
· last 1 settled
Q4 2022 Annualized Revenue
Q4 2022 Annualized
guided $320M – $350M
$284.28M
Miss −15.1%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
0%
Neutral
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
40%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Flat
0% holders QoQ
Insider flow
Accumulating
Net +$1.0M over 90 days · 0% sells
Short interest
Rising
0.37% of float · ▲ +299.5% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
2 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 40%
Range high $1
vs 200-day avg +7%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (Non-GAAP) non-GAAP | $13.34M | three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP EBITDA (Non-GAAP) 10.81M
+312K Non-cash share-based compensation
-333K Fair value changes in derivatives
+1.33M Long-lived asset impairment
+39K Loss on debt extinguishment/modification
+1.18M Other (income) expense, net
= Adjusted EBITDA (Non-GAAP) 13.34M
|
|||
| EBITDA (Non-GAAP) non-GAAP | $10.81M | three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net loss -7.33M
-976K Income tax (benefit) expense
+9.89M Interest expense, net
+9.23M Depreciation and amortization
= EBITDA (Non-GAAP) 10.81M
|
|||
| Jushi-branded product sales as a percentage of retail revenue | 57% | three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JUSH
this stock
Jushi Holdings Inc.
|
$109.43M | -13.1% | +2.1% | — | 0.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$64.15B | +27.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$49.23B | +1.9% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$46.21B | +30.2% | +4.3% | 65.0 | 2.6% |
|
HLN
Haleon plc
|
$44.06B | -0.9% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
2
- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- MFA WEALTH ADVISORS, LLC
Held
Float
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JUSH | -0.1% | -14.3% | +5.3% | +9.5% | -13.1% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -0.6% | -15.0% | -2.3% | +8.2% | -26.5% |